In parallel, researchers need to develop biomarkers that predict and monitor CD8+ T-cell responses in real time, and dissect the immunosuppressive networks that sustain tumor “coldness”; and the ultimate goal is to convert prostate cancer into an immunologically “hot” state. The gene discussed is CD8A; the disease is prostate cancer.